Clinical Trial Update: Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

An ongoing Phase 1/Phase 2 clinical trial is evaluating the combination of Samarium-153 lexidronam with docetaxel in patients with prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Quadramet (samarium-153 lexidronam pentasodium)

Snippet

Sponsor: Cytogen Corporation | Conditions: Prostatic Neoplasms | Phase 1, Phase 2 | Status: UNKNOWN